Meprin β is specifically inhibited by its cognate synthetic propeptide
In a development that could reshape how scientists approach diseases ranging from Alzheimer’s to inflammatory bowel disease, researchers have engineered a highly specific inhibitor of the enzyme meprin β — a zinc-dependent metalloprotease long implicated in a series of devastating pathological conditions. The study, published in Cellular and Molecular Life Sciences, demonstrates that a synthetic version of the enzyme’s own propeptide, the molecular safety cap that keeps the dormant enzyme in check, can shut down meprin β with remarkable selectivity while leaving closely related proteases untouched.
The significance of this work lies in the specificity problem that has plagued protease drug development for decades. Meprin β belongs to the astacin family of metalloproteases, a group of enzymes that share a common catalytic architecture centered on a zinc ion held within the active site. Existing small-molecule inhibitors, such as marimastat and actinonin, work by mimicking peptide substrates and chelating that catalytic zinc. The trouble is that these compounds cannot tell the difference between meprin β and the dozens of other metalloproteases that perform essential housekeeping functions throughout the body. The result is a therapeutic window so narrow that broad-spectrum metalloprotease inhibitors have repeatedly failed in clinical settings, producing musculoskeletal side effects that outweighed their benefits. What the new study offers instead is a molecule derived from the enzyme’s own biological regulation system — a lock designed by evolution for one key.
Meprin β is highly expressed in the kidney and intestine, and its dysregulation has been documented in Alzheimer’s disease, several cancers, fibrosis, and inflammatory bowel disease. In the context of neurodegeneration, meprin β is known to cleave the amyloid precursor protein, setting in motion biochemical events linked to the formation of amyloid-β peptides. In inflammatory conditions, the enzyme sheds the interleukin-6 receptor from cell surfaces, amplifying pro-inflammatory signaling. By cleaving the G protein-coupled receptor latrophilin-3, it may influence neural circuit formation. Each of these substrates represents a thread connecting meprin β activity to human disease, and each has made the enzyme an attractive but elusive drug target.
The molecular logic behind the new inhibitor draws on a fundamental feature of protease biology. Most proteases are synthesized as inactive zymogens, and in the astacin family, this inactivity is enforced by the propeptide — an N-terminal extension that physically occupies the enzyme’s own active site. During normal maturation, the propeptide is cleaved away, liberating the active enzyme. The research team, led by Christoph Becker-Pauly of Kiel University together with Irit Sagi of the Weizmann Institute of Science and an international consortium of collaborators, hypothesized that a synthetic copy of this propeptide, supplied in free form, would re-occupy the active site and act as a competitive inhibitor. Because the propeptide sequence is unique to meprin β, the approach should offer selectivity that generic zinc-chelating molecules cannot match.
The experiments confirmed the hypothesis with impressive quantitative precision. The synthetic wild-type propeptide inhibited meprin β with a half-maximal inhibitory concentration, or IC50, of 1.35 micromolar — a respectable figure for a peptide inhibitor. Critically, the researchers showed that the compound did not meaningfully inhibit meprin α, the closest relative of meprin β, nor did it affect members of the ADAM family of metalloproteases, which share overlapping substrates and physiological niches. In a field where off-target activity has derailed countless drug candidates, this degree of discrimination is a substantial achievement.
But the team did not stop at simply copying nature. Through a targeted structure-function analysis, they discovered that removing the last four amino acids from the C-terminal end of the propeptide significantly enhanced its inhibitory power, improving the IC50 to 0.68 micromolar — roughly a doubling of potency. This truncated variant, designated propeptideΔC, presumably gains this advantage by reducing steric interference or unfavorable electrostatic interactions that limit how deeply and stably the native propeptide can nestle into the catalytic cleft. The finding illustrates a recurring theme in modern enzymology: evolutionary optimized molecules are excellent starting points, but rational modification can push them further.
The researchers then moved beyond purified protein systems to test whether the inhibitor would function in biologically realistic environments. In cell-based experiments using HEK293T cells deficient in ADAM10 and ADAM17 — a design choice that ensured any observed effects could be attributed specifically to meprin β — treatment with the propeptide diminished meprin β activity and reduced cleavage of its substrates. Two substrates drew particular attention: the interleukin-6 receptor, whose shedding by meprin β contributes to inflammatory signaling cascades, and latrophilin-3, an adhesion G protein-coupled receptor involved in synapse formation. In both cases, the inhibitor decreased proteolytic processing, demonstrating that the compound penetrates the cellular environment effectively enough to modulate enzyme function at physiologically relevant targets.
The most demanding test came in an ex vivo model that bridges the gap between cell culture and whole organisms: organotypic brain slice cultures. These cultivated slices preserve much of the cellular architecture and diversity of living brain tissue, making them far more informative than dissociated cell cultures for neuroscience applications. When the researchers administered the propeptide to these brain slices, they observed the same pattern of results — decreased meprin β activity and diminished cleavage of latrophilin-3. This finding is particularly significant for the Alzheimer’s disease connection, as it suggests the inhibitor can function in neural tissue where the enzyme’s pathological roles are most consequential.
The methodological toolkit deployed in the study reflects the sophistication of contemporary protease research. The team used fluorescence-based enzyme assays with quenched fluorescent substrates to quantify inhibitory potency, and microscale thermophoresis to measure binding between the propeptide and the enzyme. Immunoblotting with antibodies specific to the cleaved and uncleaved forms of substrates allowed the researchers to track proteolytic events in cells and tissue slices. The use of genetically modified cells lacking ADAM10 and ADAM17 ruled out confounding contributions from these abundant sheddases, which otherwise share substrates with meprin β. Together, these approaches produced a rigorous, multi-layered body of evidence supporting the inhibitor’s specificity and efficacy.
The therapeutic implications extend across multiple disease areas. In inflammatory bowel disease, where meprin β expression patterns are altered and the enzyme contributes to epithelial barrier disruption and cytokine signaling, a selective inhibitor could dampen pathological inflammation without impairing the broader metalloprotease functions needed for tissue repair. In fibrosis, where unregulated proteolysis remodels the extracellular matrix, targeted inhibition might slow disease progression. In cancer, where meprin β activity has been linked to tumor progression and invasion, the inhibitor offers a potential anti-metastatic strategy. And in Alzheimer’s disease, the connection to amyloid precursor protein processing makes meprin β inhibition an intriguing preventive or disease-modifying approach — one that the organotypic brain slice data directly support.
Several challenges remain before this molecular concept can be translated into a medicine. Peptide inhibitors face well-known pharmacological hurdles: they are vulnerable to degradation by other proteases, they do not readily cross cell membranes, and delivering them across the blood-brain barrier for central nervous system applications remains one of pharmacology’s most persistent difficulties. The 0.68 micromolar IC50 of the truncated variant is promising but will likely need improvement through further medicinal chemistry optimization, perhaps through cyclization, non-natural amino acid incorporation, or peptidomimetic strategies that preserve the binding interface while enhancing stability. The researchers’ demonstration that systematic C-terminal modification can improve potency suggests clear avenues for such optimization.
The conceptual contribution of the study may ultimately prove as important as the practical one. The propeptide-based strategy exploits a form of biological specificity that is inherently difficult for small-molecule screens to replicate: the evolutionary co-adaptation of an enzyme and its own regulatory element. This approach could, in principle, be extended to other astacin-family proteases and to the broader family of metalloproteases, each of which carries its own unique propeptide sequence as a blueprint for selective inhibition. At a time when the pharmaceutical industry continues to grapple with the attrition of broad-spectrum enzyme inhibitors, the demonstration that nature’s own off-switches can be reverse-engineered into drug candidates offers both a practical tool and a conceptual template.
The work was supported by the Deutsche Forschungsgemeinschaft and the Alzheimer Forschung Initiative e.V., and involved collaboration among researchers at Kiel University, the Weizmann Institute of Science, the National and Kapodistrian University of Athens, the University Medical Center Mainz, and Lyon University. The study is published open access, making the detailed methods and data available to researchers worldwide who may wish to build on this approach.
Subject of Research: Development of a highly specific synthetic propeptide inhibitor targeting the metalloprotease meprin β for potential therapeutic application
Subject of Research: Biology
Article Title: Meprin β is specifically inhibited by its cognate synthetic propeptide
Article References: Armbrust, F., Bruhn, H., Bickenbach, K., Steen, N., Shcoory, S., Afratis, N., Korn, N., Körschgen, H., Moali, C., Pietrzik, C. U., Sagi, I., & Becker-Pauly, C. (2026). Meprin β is specifically inhibited by its cognate synthetic propeptide. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06361-4
Image Credits: AI Generated
DOI: 10.1007/s00018-026-06361-4
Keywords: Meprin β, metalloprotease, propeptide inhibitor, IL-6R, Latrophilin-3, amyloid precursor protein, Alzheimer’s disease, inflammation, protease specificity, drug development
Cite Scienmag News
APA MLA Chicago
Drew Townsend. (September 8, 2026). Meprin β enzyme selectively blocked by its own synthetic propeptide. Scienmag. https://scienmag.com/meprin-%ce%b2-enzyme-selectively-blocked-by-its-own-synthetic-propeptide/
Drew Townsend. “Meprin β enzyme selectively blocked by its own synthetic propeptide.” Scienmag, 8 September 2026, https://scienmag.com/meprin-%ce%b2-enzyme-selectively-blocked-by-its-own-synthetic-propeptide/. Accessed 8 September 2026.
Drew Townsend. “Meprin β enzyme selectively blocked by its own synthetic propeptide.” Scienmag. September 8, 2026. https://scienmag.com/meprin-%ce%b2-enzyme-selectively-blocked-by-its-own-synthetic-propeptide/
Copy citation Download RIS
Tags: advances in enzyme inhibitor selectivityAlzheimer’s disease enzyme targetsastacin family metalloproteaseschallenges in metalloprotease inhibitor designenzyme specificity in drug developmentenzyme-specific therapeutic developmentimplications for Alzheimer’s and inflammatory bowel diseaseinflammatory bowel disease enzyme inhibitorsMeprin β enzyme inhibitionmetalloprotease drug specificitymetalloprotease enzyme regulationmetalloprotease enzyme targetingpropeptide-based enzyme regulationprotease drug design challengesprotein safety caps in enzyme controlselective protease inhibition strategiesselectivity in enzyme inhibitionsynthetic propeptide as specific inhibitorsynthetic propeptide inhibitorstherapeutic targeting of meprin βzinc-dependent protease regulationzinc-dependent protease targeting
